Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004

Impact · against what's priced in

Eikon Therapeutics reveals promising early-stage selectivity and clinical signals for its PARP1 and Werner helicase programs, though the discovery of an off-target cardiac effect for EIK1003 introduces a manageable safety risk. The combination of high enzymatic selectivity and the potential for brain penetration with EIK1004 provides a clear path toward differentiation from first-generation PARP inhibitors.

EIKN+0.40

No priced-in read yet